Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

Hong Kong’s Travel Platform Klook Closes $200 Million Funding Round Amid Virus Travel Restrictions
Venture Capital Firm Qiming Raises $441 Million for Yuan-Denominated Fund for Startups
Baidu Juices Up Intelligent Driving Tie-Up With BlackBerry
India Permanently Rolls Back Welcome Matt on TikTok, WeChat and Other Chinese Apps
Will Faraday and Geely Team Up in a Possible Replication of Baidu and Foxconn Manufacturing Partnerships?
Chinese Edtech Startup Huohua Siwei Secures $400 Million in Series E Funding Round
Trending in China: Man Fired for Skipping Work to Mourn Father Gets Billion Views
Impressive New York Trading Debut for Chinese E-Cigarette Maker RLX But Challenges Lie Ahead
Self-Driving Tech Startup Uisee Closes $155 Million Funding Round
Trending in China: Gold Mining Rescue Lights Up Weibo
China Evergrande’s NEV Unit Brings Six Investors On Board to Raise $3.4 Billion
Taiwan’s MediaTek Surpasses Qualcomm as China’s Smartphone Chip Supplier of Choice as U.S. Sanctions Bite
Tencent-Backed Esports Startup VSPN Closes $60 Million Funding
Trending in China: Foreign Medical Students Volunteer for Battle Against Virus in Freezing Northeast
Chinese Telcos Look for More Sympathy Under Biden Administration
Gojek, Tokopedia Explore Holding Company Structure as Merger Talks Move Forward
Carmaker BYD to Raise $3.9 Billion Through New Share Sale
Trending in China: Beijing Skating Now On Ice As Covid Restrictions Imposed
Alibaba’s Jack Ma Reemerges After Long Absence
Chinese Mainland Speeds Up Chip Equipment Buying from ASML
Astra Inks Oxford Vaccine Production Deal with China’s Kangtai

By Bloomberg / Aug 07, 2020 04:24 AM / Business & Tech



AstraZeneca Plc and China’s Shenzhen Kangtai Biological Products Co. entered a deal to produce the U.K. drugmaker’s promising Covid-19 vaccine, the latest in a flurry of global pacts aimed at fighting the pandemic.

Shenzhen Kangtai agreed to build capacity to make at least 100 million doses of the shot by year-end, and 200 million by the end of 2021, Astra said Thursday on its WeChat account. The companies will also look at working together on the jab — designed by scientists at the University of Oxford — for other markets.

Astra has already struck deals to supply hundreds of millions of doses of the experimental vaccine for the U.K., U.S. and Europe. The British drugmaker has said it will supply the shot at cost during the period of the pandemic, and hasn’t disclosed how much it will charge after. Astra has committed to starting delivery of 30 million vaccine doses to the U.K. by September.

Shenzhen Kangtai is one of China’s biggest vaccine makers, with shots against diseases such as pneumonia and measles. Many of its products employ more sophisticated techniques, including genetic engineering. It’s also a major supplier of hepatitis B vaccine.

Share this article
Open WeChat and scan the QR code